ÜBER DIESE EPISODE
Alice Lin, DCT Solutions Director in the DCT Business Department of Tigermed Consulting, a global CRO, contract research organization, that provides biopharmaceutical and medical device companies with a range of services including digital technology to conduct decentralized clinical trials. Their approach focuses on patient-centricity, efficiency, and adaptability. By utilizing digital tools such as virtual visits, wearable devices, and mobile apps, Tigermed aims to make clinical trials more accessible and convenient for patients, improving recruitment and retention rates. They also emphasize the importance of DCT in including a diverse patient population in trials, particularly for rare diseases.
Alice explains, "While our headquarters is in China, we have grown into a global team of over 10,000 employees operating across over 180 locations worldwide. We recently celebrated our 20th anniversary, making two decades of dedicated collaborations with over 2,800 customers on their product journeys. DCT stands for decentralized clinical trials, which involves applying digital technologies to conduct clinical trials. Traditionally, most clinical trial activities are conducted at clinical sites. Still, with DCT, we can conduct some or even all of the trial procedures outside of these sites using digital technology."
"Currently, the hybrid DCT model is a common thing in clinical trials. It means some of the trial procedures could be conducted outside of clinical sites, but still keep some clinical trial activities at clinical sites. In our Tigermed DCT department, we are responsible for identifying the appropriate digital technologies for using in clinical trials, whether through self-development or collaboration with the various digital technology companies. We also manage the DCT daily operations in each clinical trial from the study beginning to the study completion."
"However, we get that every investigational product and the therapeutic areas bring its own set of challenges and patient needs. So, we make it a priority to figure out what digital tools work best for each study. Our CEO, Dr. Cao, and our head of the DCT business department always say our goal is not just to do decentralized clinical trials for the sake of it. It's about giving patients and caregivers options that fit their needs. This approach means patients and caregivers get solutions that work for them, showing that we are all about being flexible to what they need. Our decentralized clinical trials are all about making things easier for patients, lightening the load for our caregivers, and making the whole trial experience better for all stakeholders involved."
#TigermedGRP #CRO #ContractResearchOrganization #DCT #DecentralizedClinicalTrials #MedTech #RemoteMonitoring
